BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  AbbVie is Enabling Students Diagnosed with Immunological Diseases to Shine

  The AbbVie Immunology Scholarship provides financial support to students living with chronic, immune-mediated diseases who are pursuing higher education in the United States.

  June 1, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Passage Bio CEO Bruce Goldsmith Abruptly Steps Down

  Although Bruce Goldsmith will no longer serve on the executive team, he will remain with Passage Bio for a short period as a strategic advisor to the interim CEO.

  June 1, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  BMS Preps Lupus Treatment to Become Third Approval in Space

  Bristol Myers Squibb (BMS) has announced late-breaking data showing deucravacitinib significant efficacy at the primary endpoint for the treatment of systemic lupus erythematosus (SLE).

  June 1, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  Report Predicts AbbVie Could Become Top-Selling Pharma Company by 2028

  The report suggests that AbbVie’s sales will be approximately $65.7 billion within the next six years, with Roche right behind at $65 billion.

  June 1, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Pfizer to Sell Stake in Haleon Following GSK De-Merger

  Pfizer intends to sell off its stake when the de-merger occurs and seek the most profitable sale of its share of Haleon to maximize value for company stockholders.

  June 1, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  FDA Pulls Approval for TG Therapeutics’ Cancer Drug

  Shares of TG Therapeutics are falling fast in Wednesday trading after the U.S. Food and Drug Administration announced it was pulling approval of the cancer drug Ukoniq (umbralisib).

  June 1, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Genetown

  MassBio Report Highlights Hiring Struggles in the Life Sciences Industry

  In a recent Massachusetts Biotechnology Council survey, 94.2% of respondents reported having difficulty hiring experienced workers.

  June 1, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Biopharma Companies Team Up to Fight Diabetes, Alzheimer’s and Cancer

  Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.

  June 1, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Transcranial Pulse Stimulation for Alzheimer’s: Legitimate Treatment or Pseudoscience?

  A largely untested and unproven treatment for Alzheimer’s disease, called transcranial pulse stimulation (TPS), is becoming popular around the world, although experts are skeptical.

  June 1, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Global Roundup: Memo Therapeutics Takes Aim at BKV Infections

  Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.

  June 1, 2022

   · 

  6 min read

   · 

  Alex Keown